A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ASN 002 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Asana BioSciences
- 03 Aug 2017 ASN002 20 mg dose has been added in treatment arm.
- 03 Aug 2017 Planned number of patients changed from 36 to 48.
- 02 May 2017 Status changed from planning to recruiting.